Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma

The integration of immune checkpoint inhibitors into frontline therapy for classical Hodgkin lymphoma (cHL) is reshaping the treatment landscape. As PD-1 blockade moves earlier in care, it alters transplant strategy, drug sequencing, and the role of established agents such as brentuximab vedotin. This article summarizes updates presented at the NCCN 2025 Annual Conference, focusing on how first-line PD-1 inhibition influences management in relapsed or refractory cHL and creates new questions around optimal treatment sequencing.